A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
- Status
- RECRUITING
- Phase
- PHASE3
Clinical Trials Related to Daratumumab
Related studies linked through entity extraction aliases.
Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
- Status
- RECRUITING
- Phase
- PHASE2
Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
- Status
- RECRUITING
- Phase
- PHASE2
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE1
Risk Stratification and MRD-driven Maintenance for MM After ASCT
- Status
- RECRUITING
- Phase
- NA
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- Status
- RECRUITING
- Phase
- PHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Status
- RECRUITING
- Phase
- PHASE3
A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Biomarkers of AKI in Patients Receiving Daratumumab
- Status
- COMPLETED
- Phase
- N/A
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
- Status
- RECRUITING
- Phase
- N/A
A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
- Status
- RECRUITING
- Phase
- PHASE3
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
- Status
- RECRUITING
- Phase
- PHASE4
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach for Patients With Anti-donor Red Cell Antibody
- Status
- RECRUITING
- Phase
- PHASE2